Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T19:41:13.707Z Has data issue: false hasContentIssue false
  • English
  • Français

Absence of contralateral suppression of transiently evoked otoacoustic emissions in fibromyalgia syndrome

Published online by Cambridge University Press:  04 March 2008

B Gunduz ,
Y A Bayazit ,
F Celenk ,
C Sarıdoğan ,
A G Guclu ,
E Orcan  and
J Meray
B Gunduz
Affiliation:
Department of Audiology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
Y A Bayazit
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
F Celenk*
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
C Sarıdoğan
Affiliation:
Department of Audiology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
A G Guclu
Affiliation:
Department of Physical Medicine, Faculty of Medicine, Hacettepe University, Turkey
E Orcan
Affiliation:
Department of Audiology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
J Meray
Affiliation:
Department of Physical Medicine, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey
*
Address for correspondence: Dr Fatih Celenk, Dept of Otolaryngology, Faculty of Medicine, Gazi University, Besevler, Ankara, Turkey. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To assess contralateral suppression of transiently evoked otoacoustic emissions in patients with fibromyalgia syndrome and normal hearing.

Methods:

Twenty-four female patients with fibromyalgia syndrome and 24 healthy female controls with normal hearing were assessed using pure tone audiometry and transiently evoked otoacoustic emissions.

Results:

All patients with fibromyalgia syndrome and all controls had normal hearing on pure tone audiometry. In the patients with fibromyalgia syndrome, the mean transiently evoked otoacoustic emission amplitude was 15.5 ± 4.8 dB. The mean transiently evoked otoacoustic emission amplitudes after contralateral suppression was 15.5 ± 4.9 dB. There was no statistically significant difference between the transiently evoked otoacoustic emission amplitudes measured before and after contralateral suppression (p > 0.05). In the controls, the mean transiently evoked otoacoustic emission amplitude was 12 ± 5 dB. The mean transiently evoked otoacoustic emission amplitudes after contralateral suppression was 11 ± 4.7 dB. There was a statistically significant decrease in transiently evoked otoacoustic emission amplitudes after contralateral suppression (p < 0.01).

Conclusion:

The mechanisms related to contralateral suppression of transiently evoked otoacoustic emissions seem dysfunctional in fibromyalgia syndrome. This dysfunction may be at the brain stem level, where the medial superior olivary complex is located, or at the synapses of medial superior olivary complex fibres with the outer hair cells in the cochlea. Demonstration of lack of contralateral suppression of transiently evoked otoacoustic emissions can be used as a diagnostic tool in patients with fibromyalgia syndrome.

Keywords

Otoacoustic EmissionsFibromyalgia
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 122 , Issue 10 , October 2008 , pp. 1047 - 1051
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Abeles, AM, Pillinger, MH, Solitar, BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;15:726–34CrossRefGoogle Scholar
2 Bayazit, YA, Gursoy, S, Ozer, E, Karakurum, G, Madenci, E. Neurotologic manifestations of the fibromyalgia syndrome. J Neurol Sci 2002;15:77–80Google Scholar
3 Waylonis, GW, Heck, W. Fibromyalgia, syndrome. New associations. Am J Phys Med Rehabil 1992;71:343–8CrossRefGoogle ScholarPubMed
4 Gerster, JC, Hadj-Djilani, A. Hearing and vestibular abnormalities in primary fibrositis syndrome. J Rheumatol 1984;11:678–80Google Scholar
5 Cook, DB, Stegner, AJ, McLoughlin, MJ. Imaging pain of fibromyalgia. Curr Pain Headache Rep 2007;11:190–200Google Scholar
6 Kwiatek, R, Barnden, L, Tedman, R, Jarrett, R, Chew, J, Rowe, C et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000;43:2823–333.0.CO;2-E>CrossRefGoogle ScholarPubMed
7 Kuchinad, A, Schweinhardt, P, Seminowicz, DA, Wood, PB, Chizh, BA, Bushnell, MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007;27:4004–7Google Scholar
8 Alnigenis, MN, Barland, P. Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol 2001;19:205–10Google Scholar
9 Carrillo-de-la-Pena, MT, Vallet, M, Perez, MI, Gomez-Perretta, C. Intensity dependence of auditory-evoked cortical potentials in fibromyalgia patients: a test of the generalized hypervigilance hypothesis. J Pain 2006;7:480–7CrossRefGoogle ScholarPubMed
10 Velenovsky, DS, Glattke, TJ. Contralateral and binaural suppression of otoacoustic emissions. In: Robinette, MS, Glattke, TJ, eds. Otoacoustic Emissions: Clinical applications, 2nd edn. New York: Thieme Medical Publishers, 2002:163–90Google Scholar
11 Maison, S, Micheyl, C, Collet, L. The medial olivocochlear efferent system in humans: structure and function. Scand Audiol 1999;28:77–84Google Scholar
12 Prasher, D, Ryan, S, Luxon, L. Contralateral suppression of transiently evoked otoacoustic emissions and neuro-otology. Br J Audiol 1994;28:247–54CrossRefGoogle ScholarPubMed
13 Wolfe, F, Smythe, HA, Yunus, MB, Bennett, RM, Bombardier, C, Goldenberg, DL et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72Google Scholar
14 Burckhardt, CS, Clark, SR, Bennett, RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728–33Google Scholar
15 De Ceulaer, G, Yperman, M, Daemers, K, Van Driessche, K, Somers, T, Offeciers, FE et al. Contralateral suppression of transient evoked otoacoustic emissions: normative data for a clinical test set-up. Otol Neurotol 2001;22:350–5CrossRefGoogle ScholarPubMed
16 Yilmaz, M, Baysal, E, Gunduz, B, Aksu, A, Ensari, N, Meray, J et al. Assessment of the ear and otoacoustic emission findings in fibromyalgia syndrome. Clin Exp Rheumatol 2005;23:701–3Google Scholar
17 Guinan, JJ. Olivocochlear efferents: anatomy, physiology, function, and the measurement of efferent effects in humans. Ear Hear 2006;27:589–607Google Scholar
18 Rosenhall, U, Johansson, G, Orndahl, G. Otoneurologic and audiologic findings in fibromyalgia. Scand J Rehabil Med 1996;28:225–32Google Scholar
19 Kujawa, SG, Glattke, TJ, Fallon, M, Bobbin, RP. A nicotinic-like receptor mediates suppression of distortion product otoacoustic emissions by contralateral sound. Hear Res 1994;74:122–34Google Scholar
20 Larson, AA, Giovengo, SL, Russell, IJ, Michalek, JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201–11Google Scholar